31 results about "Drugs identified" patented technology

A system and method for identifying safety concerns regarding a drug identify a first group of patients that have received the drug from a database of healthcare claims and extract one or more medical events that the first group of patients have experienced from the database. The system and method also identify a second group of patients that have received a comparator drug in the database and extract one or more medical events that the second group of patients have experienced. The medical events of the first group are compared to the medical events of the second group to determine at least one common occurrence therebetween. The common occurrence(s) is then filtered based upon one or more user defined outcomes, each including at least one diagnosis, procedure or therapeutic classification; non-medical criteria; and / or patient laboratory test data.

A computer implemented system and method for matching drugs and diseases involves matching drugs identified in a specific patient's prescription claim records with diseases identified in the patient's medical claims. A weighted relationship is generated between the matched drugs and diseases by calculating a link weight in accordance with a preprogrammed formula for each of the diagnosis codes identified in the patient's medical claims that is identified as associated with the disease identified and the drug. The link weight provides a statistical match association value to each of the matched diseases identified by way of a diagnosis code in the patient's medical claim and the drug identified in the prescription claim.

The invention provides a compound, useful as an optical probe or sensor of the activity of at least one cytochrome P450 enzyme, and methods of using the compound to screen candidate drugs, and candidate drugs identified by these methods. The optical probe of the invention is a compound having the generic structure Y-L-Q, wherein Y is selected from the group consisting of Q as herein defined, saturated C1-C20 alkyl, unsaturated C1-C20 alkenyl, unsaturated C1-C20 alkynyl, substituted saturated C1-C20 alkyl, substituted unsaturated C1-C20 alkenyl, substituted unsaturated C1-C20 alkynyl, C1-C20 cycloalkyl, C1-C20 cycloalkenyl, substituted saturated C1-C20 cycloalkyl, substituted unsaturated C1-C20 cycloalkenyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl; L is selected from the group of (—OCR2H)p—, wherein for each p, all R2 are separately selected from the group consisting of a hydrogen atom, saturated C1-C20 alkyl, unsaturated C1-C20 alkenyl, unsaturated C1-C20 alkynyl, substituted saturated C1-C20 alkyl, substituted unsaturated C1-C20 alkenyl, substituted unsaturated C1-C20 alkynyl, C1-C20 cycloalkyl, C1-C20 cycloalkenyl, substituted saturated C1-C20 cycloalkyl, substituted unsaturated C1-C20 cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, and p is a positive integer no greater than twelve; and Q is a chemical moiety that gives rise to optical properties in its hydroxy or hydroxylate, phenol or phenoxide form that are different from the optical properties that arise from its ether form. Most preferably, p is one, R2 is hydrogen, and Q is the ether form of a phenoxide fluorophore.

The invention provides a weighted PageRank algorithm-based method and system for quantifying drug attributes of prescriptions, which helps to improve the accuracy of PR values ​​of drug attributes. The method includes: decomposing the drug attributes of each drug in the prescription, determining the drug attributes of the prescription and the weights of the drug attributes; using the drug attributes in the prescription as drug attribute nodes in the network link structure, and according to different drug attributes According to the interaction between the drug attribute nodes, the network link structure diagram between the drug attribute nodes is constructed; according to the determined weight of the drug attribute, the weighted PageRank algorithm is used to iterate the drug attribute nodes to determine the PR value of the drug attribute. The invention is applicable to the technical field of medicine attribute quantification.

The present invention provides methods for promoting generation of heart tissue, and for treating and preventing heurt tissue degeneration. Additionally, the present invention provides a therapeutic composition comprising a cyclin-associated agent, and a kit comprising the composition. The present invention further provides a heart tissue tell, a sidepopulation progenitor tell, and a stem tell in which cyclin is augmented. Also provided are tell lins comprising these tells, screening methods using the tell lins, and drugs identified by these methods. The present invention further provides in vitro systems for use in screening candidate drugs for at least one cardiotoxic effect and / or for synergy with cyclin in the treatment and prevention of heart tissue degeneration. Finally, the present invention provides use of a cyclin-associated agent in the generation of heart tissue, and use of a cyclin associated agent in the treatment or prevention of heart tissue degeneration.

The present application discloses a method and device for monitoring a drug compounding system. The drug compounding system has at least one environmental monitoring device for monitoring internal environmental conditions of the drug compounding system. The method of monitoring a drug compounding system includes: acquiring environmental data representing internal environmental conditions at one or more locations in the drug compounding system; processing the acquired environmental data to determine anomalies in the internal environmental conditions of the drug compounding system; And according to the determined abnormality of the internal environment of the drug compounding system, determine an operation action for the drug compounding system.